Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

A specific graft-versus-host disease prophylaxis regimen may expand allogeneic hematopoietic stem cell transplant access to ...

A "hybrid" immune system approach may prevent or cure Type 1 diabetes (T1D) by combining blood stem cell and islet cell transplants. The method uses a nonmyeloablative conditioning regimen to prevent ...

For years, the search for a stem cell donor has felt like a quest for a rare key—one that fits a lock with eight intricate ...

Together, Kevin and Jaqi face graft-versus-host disease (GVHD), a complication that can occur following a bone marrow ...